Using Dendritic Cells to Create Cancer Vaccines for Melanoma
Author Information
Author(s): Markovic Svetomir N, Dietz Allan B, Greiner Carl W, Maas Mary L, Butler Greg W, Padley Douglas J, Bulur Peggy A, Allred Jacob B, Creagan Edward T, Ingle James N, Gastineau Dennis A, Vuk-Pavlovic Stanimir
Primary Institution: Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Hypothesis
Can electroporation-mediated transfection of myeloid dendritic cells with tumor-derived mRNA be a standardized method for preparing clinical-grade DC vaccines?
Conclusion
Standardized preparation of viable clinical-grade DCs transfected with tumor-derived and in vitro amplified mRNA is feasible and their administration is safe.
Supporting Evidence
- Electrotransfection did not affect the viability and phenotype of fresh mature dendritic cells.
- No patient exhibited grade 3 or 4 toxicity upon dendritic cell injections.
- Post-thaw viability was lower in electroporated cells compared to non-electroporated cells.
Takeaway
Researchers are trying to make vaccines from special immune cells called dendritic cells to help fight melanoma, and they found a safe way to prepare these vaccines.
Methodology
Dendritic cells were prepared from patients' blood, transfected with tumor-derived mRNA using electroporation, and then injected into patients to test safety.
Limitations
The study had a small sample size and did not observe significant clinical responses due to the advanced stage of melanoma in patients.
Participant Demographics
Six patients with stage IV malignant melanoma, aged 40 to 66, with a mix of genders.
Statistical Information
P-Value
0.001
Statistical Significance
p = 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website